These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 16397313

  • 1. Myelotoxicity and hepatotoxicity during azathioprine therapy.
    de Boer NK, Mulder CJ, van Bodegraven AA.
    Neth J Med; 2005 Dec; 63(11):444-6. PubMed ID: 16397313
    [Abstract] [Full Text] [Related]

  • 2. Suspected azathioprine induced liver cirrhosis: an unusual side effect.
    Trabelsi AB, Hamami E, Souguir A, Ksiaa M, Ajmi S, Jmaa A.
    Pan Afr Med J; 2014 Dec; 17():174. PubMed ID: 25392720
    [Abstract] [Full Text] [Related]

  • 3. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B.
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [Abstract] [Full Text] [Related]

  • 4. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K, Schaeffeler E, Lukas M, Strauch U, Herfarth H, Müller R, Schwab M.
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [Abstract] [Full Text] [Related]

  • 5. [Portal vein hypertension during azathioprine therapy in patients with Crohn's disease--a frequent phenomenon?].
    Ehmsen L, Marko C, Breidert M.
    Dtsch Med Wochenschr; 2008 May; 133(18):950-3. PubMed ID: 18431703
    [Abstract] [Full Text] [Related]

  • 6. Paradoxical elevated thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age.
    de Boer NK, van Bodegraven AA, de Graaf P, van der Hulst RW, Zoetekouw L, van Kuilenburg AB.
    Ther Drug Monit; 2008 Jun; 30(3):390-3. PubMed ID: 18520612
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's disease.
    Herrlinger KR, Fellermann K, Fischer C, Kreisel W, Deibert P, Schoelmerich J, Fleig WE, Ruhl A, Reinshagen M, Greinwald R, Stange EF, Schwab M.
    Aliment Pharmacol Ther; 2004 Jun 15; 19(12):1269-76. PubMed ID: 15191508
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Nodular regenerative hyperplasia: azathioprine-induced hepatotoxicity in a patient with Crohn's disease].
    López-Martín C, de la Fuente-Fernández E, Corbatón P, Sánchez MC, Gisbert JP.
    Gastroenterol Hepatol; 2011 Jan 15; 34(1):16-9. PubMed ID: 21168244
    [Abstract] [Full Text] [Related]

  • 11. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY, Devlin SM, Mirocha JM, Papadakis KA.
    Dig Liver Dis; 2008 Jun 15; 40(6):425-32. PubMed ID: 18304898
    [Abstract] [Full Text] [Related]

  • 12. Nodular regenerative liver hyperplasia as a complication of azathioprine-containing immunosuppressive treatment for Crohn's disease.
    Błogowski W, Marlicz W, Smereczyński A, Lawniczak M, Lewosiuk A, Starzyńska T.
    Immunopharmacol Immunotoxicol; 2011 Jun 15; 33(2):398-402. PubMed ID: 20726808
    [Abstract] [Full Text] [Related]

  • 13. Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center.
    Banerjee S, Bishop WP.
    J Pediatr Gastroenterol Nutr; 2006 Sep 15; 43(3):324-30. PubMed ID: 16954954
    [Abstract] [Full Text] [Related]

  • 14. On the limitation of 6-tioguaninenucleotide monitoring during tioguanine treatment.
    de Boer NK, de Graaf P, Wilhelm AJ, Mulder CJ, van Bodegraven AA.
    Aliment Pharmacol Ther; 2005 Sep 01; 22(5):447-51. PubMed ID: 16128683
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency.
    Yenson PR, Forrest D, Schmiegelow K, Dalal BI.
    Am J Hematol; 2008 Jan 01; 83(1):80-3. PubMed ID: 17696202
    [Abstract] [Full Text] [Related]

  • 18. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
    Gisbert JP, Niño P, Rodrigo L, Cara C, Guijarro LG.
    Am J Gastroenterol; 2006 Dec 01; 101(12):2769-76. PubMed ID: 17026564
    [Abstract] [Full Text] [Related]

  • 19. [Nodular regenerative hyperplasia as a side effect of azathioprine in a patient with Crohn's disease].
    Schumann M, Preiss JC, Loddenkemper C, Günther U, Somasundaram R, Siegmund B, Zeitz M.
    Dtsch Med Wochenschr; 2008 Sep 01; 133(38):1897-900. PubMed ID: 18788068
    [Abstract] [Full Text] [Related]

  • 20. [Severe varicella zoster pneumonia during the course of treatment with azathioprine for Crohn's disease].
    Lemyze M, Tavernier JY, Chevalon B, Lamblin C.
    Rev Mal Respir; 2003 Nov 01; 20(5 Pt 1):773-6. PubMed ID: 14631259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.